FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2266394333> ?p ?o ?g. }

• W2266394333 endingPage "167" @default.
• W2266394333 startingPage "167" @default.
• W2266394333 abstract "To assess the feasibility of administering PN401, an oral uridine prodrug, as a rescue agent for the toxic effects of fluorouracil (5-FU), and to determine the maximum-tolerated dose of 5-FU when given with PN401, with an 8-hour treatment interval between these agents.Patients with advanced solid malignancies were treated with escalating doses of 5-FU, given as a rapid intravenous infusion weekly for 3 consecutive weeks every 4 weeks. PN401 was administered orally 8 hours after 5-FU administration, to achieve sustained plasma uridine concentrations of at least 50 micromol/L. Initially, patients received 6 g of PN401 orally every 8 hours for eight doses (schedule 1). When dose-limiting toxicity (DLT) was consistently noted, patients then received 6 g of PN401 every 2 hours for three doses and every 6 hours thereafter for 15 doses (schedule 2).Twenty-three patients received 50 courses of 5-FU and PN401. Among patients on schedule 1, DLT (grade 4 neutropenia complicated by fever and diarrhea) occurred in those receiving 5-FU 1,250 mg/m(2)/wk. Among patients on schedule 2, 5-FU 1,250 mg/m(2)/wk was well tolerated, but grade 4, protracted (> 5 days) neutropenia was consistently noted in those treated with higher doses of the drugs. Nonhematologic effects were uncommon and rarely severe. The pharmacokinetics of 5-FU, assessed in 12 patients on schedule 2, were nonlinear, with the mean area under the time-versus-concentration curve (AUC) increasing from 298 +/- 44 to 962 +/- 23 micromol/L and mean clearance decreasing from 34 +/- 4 to 15.6 +/- 0.38 L/h/m(2) as the dose of 5-FU was increased from 1,250 to 1,950 mg/m(2)/wk. 5-FU AUCs achieved with 5-FU 1,250 mg/m(2)/wk for 6 weeks along with the intensified PN401 dose schedule were approximately five-fold higher than those achieved with 5-FU alone. Plasma uridine concentrations increased with each of the three PN401 doses given every 2 hours, and uridine steady-state concentrations were greater than 50 micromol/L.Treatment with oral PN401 beginning 8 hours after 5-FU administration is well tolerated and results in sustained plasma uridine concentrations above therapeutic-relevant levels. The recommended 5-FU dosage for phase II evaluations is 1,250 mg/m(2)/wk for 3 weeks every 4 weeks with the intensified PN401 dose schedule (schedule 2). At this dose, systemic exposure to 5-FU as measured by AUC was five-fold higher than that observed after administration of a conventional 5-FU bolus." @default.
• W2266394333 created "2016-06-24" @default.
• W2266394333 creator A5001759866 @default.
• W2266394333 creator A5002037553 @default.
• W2266394333 creator A5011136805 @default.
• W2266394333 creator A5011905014 @default.
• W2266394333 creator A5015548619 @default.
• W2266394333 creator A5025571257 @default.
• W2266394333 creator A5036762586 @default.
• W2266394333 creator A5046194087 @default.
• W2266394333 creator A5048907012 @default.
• W2266394333 creator A5054400680 @default.
• W2266394333 creator A5058784740 @default.
• W2266394333 creator A5063294358 @default.
• W2266394333 creator A5073306541 @default.
• W2266394333 creator A5074044801 @default.
• W2266394333 creator A5080900202 @default.
• W2266394333 creator A5086660695 @default.
• W2266394333 date "2000-01-01" @default.
• W2266394333 modified "2023-10-16" @default.
• W2266394333 title "Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients With Advanced Solid Malignancies" @default.
• W2266394333 cites W1581888219 @default.
• W2266394333 cites W1811602282 @default.
• W2266394333 cites W1962361812 @default.
• W2266394333 cites W1969387370 @default.
• W2266394333 cites W1977870292 @default.
• W2266394333 cites W1993393197 @default.
• W2266394333 cites W1996662766 @default.
• W2266394333 cites W2037201734 @default.
• W2266394333 cites W2049807473 @default.
• W2266394333 cites W2059247762 @default.
• W2266394333 cites W2088824574 @default.
• W2266394333 cites W2088912619 @default.
• W2266394333 doi "https://doi.org/10.1200/jco.2000.18.1.167" @default.
• W2266394333 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10623707" @default.
• W2266394333 hasPublicationYear "2000" @default.
• W2266394333 type Work @default.
• W2266394333 sameAs 2266394333 @default.
• W2266394333 citedByCount "24" @default.
• W2266394333 countsByYear W22663943332012 @default.
• W2266394333 countsByYear W22663943332013 @default.
• W2266394333 countsByYear W22663943332014 @default.
• W2266394333 countsByYear W22663943332016 @default.
• W2266394333 countsByYear W22663943332019 @default.
• W2266394333 countsByYear W22663943332021 @default.
• W2266394333 countsByYear W22663943332022 @default.
• W2266394333 crossrefType "journal-article" @default.
• W2266394333 hasAuthorship W2266394333A5001759866 @default.
• W2266394333 hasAuthorship W2266394333A5002037553 @default.
• W2266394333 hasAuthorship W2266394333A5011136805 @default.
• W2266394333 hasAuthorship W2266394333A5011905014 @default.
• W2266394333 hasAuthorship W2266394333A5015548619 @default.
• W2266394333 hasAuthorship W2266394333A5025571257 @default.
• W2266394333 hasAuthorship W2266394333A5036762586 @default.
• W2266394333 hasAuthorship W2266394333A5046194087 @default.
• W2266394333 hasAuthorship W2266394333A5048907012 @default.
• W2266394333 hasAuthorship W2266394333A5054400680 @default.
• W2266394333 hasAuthorship W2266394333A5058784740 @default.
• W2266394333 hasAuthorship W2266394333A5063294358 @default.
• W2266394333 hasAuthorship W2266394333A5073306541 @default.
• W2266394333 hasAuthorship W2266394333A5074044801 @default.
• W2266394333 hasAuthorship W2266394333A5080900202 @default.
• W2266394333 hasAuthorship W2266394333A5086660695 @default.
• W2266394333 hasConcept C112705442 @default.
• W2266394333 hasConcept C126322002 @default.
• W2266394333 hasConcept C141071460 @default.
• W2266394333 hasConcept C2776694085 @default.
• W2266394333 hasConcept C2777063308 @default.
• W2266394333 hasConcept C2779802037 @default.
• W2266394333 hasConcept C2780456651 @default.
• W2266394333 hasConcept C29730261 @default.
• W2266394333 hasConcept C42219234 @default.
• W2266394333 hasConcept C71924100 @default.
• W2266394333 hasConcept C90924648 @default.
• W2266394333 hasConceptScore W2266394333C112705442 @default.
• W2266394333 hasConceptScore W2266394333C126322002 @default.
• W2266394333 hasConceptScore W2266394333C141071460 @default.
• W2266394333 hasConceptScore W2266394333C2776694085 @default.
• W2266394333 hasConceptScore W2266394333C2777063308 @default.
• W2266394333 hasConceptScore W2266394333C2779802037 @default.
• W2266394333 hasConceptScore W2266394333C2780456651 @default.
• W2266394333 hasConceptScore W2266394333C29730261 @default.
• W2266394333 hasConceptScore W2266394333C42219234 @default.
• W2266394333 hasConceptScore W2266394333C71924100 @default.
• W2266394333 hasConceptScore W2266394333C90924648 @default.
• W2266394333 hasIssue "1" @default.
• W2266394333 hasLocation W22663943331 @default.
• W2266394333 hasLocation W22663943332 @default.
• W2266394333 hasOpenAccess W2266394333 @default.
• W2266394333 hasPrimaryLocation W22663943331 @default.
• W2266394333 hasRelatedWork W2017564324 @default.
• W2266394333 hasRelatedWork W2112528869 @default.
• W2266394333 hasRelatedWork W2114878163 @default.
• W2266394333 hasRelatedWork W2352350815 @default.
• W2266394333 hasRelatedWork W2363374489 @default.
• W2266394333 hasRelatedWork W2366943731 @default.
• W2266394333 hasRelatedWork W2908757458 @default.
• W2266394333 hasRelatedWork W2991030316 @default.

• next